Cargando…
EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201
Diffuse midline glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, with patients rarely surviving 2 years from diagnosis. We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). Patients enrolled on Arm D of the tr...
Autores principales: | Cantor, Evan, Wierzbicki, Kyle, Tarapore, Rohinton S, Thomas, Chase, Cartaxo, Rodrigo, Yadav, Viveka Nand, Ravindran, Ramya, Bruzek, Amy K, Wadden, Jack, Babilla, Clarissa May, Kawakibi, Abed Rhaman, Ji, Sunjong, Ramos, Johanna, Paul, Alyssa, Wolfe, Ian, Leonard, Marcia, Robertson, Partricia, Franson, Andrea, Mody, Rajen, Garton, Hugh, Odia, Yazmin, Kline, Cassie, Vitanza, Nicholas A, Khatua, Soumen, Mueller, Sabine, Allen, Joshua E, Gardner, Sharon, Koschmann, Carl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263166/ http://dx.doi.org/10.1093/neuonc/noab090.189 |
Ejemplares similares
-
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma
por: Cantor, Evan, et al.
Publicado: (2022) -
EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL
por: Roberts, Holly, et al.
Publicado: (2021) -
EPCT-07. ID1 IS A KEY TRANSCRIPTIONAL REGULATOR OF DIPG INVASION AND IS TARGETABLE WITH CANNABIDIOL
por: Nand Yadav, Viveka, et al.
Publicado: (2021) -
EPCT-06. A PHASE I STUDY OF MULTI-TARGETED THERAPY IN NEWLY DIAGNOSED OR PROGRESSIVE DIFFUSE INTRINSIC PONTINE GLIOMA
por: Baig, Muhammad, et al.
Publicado: (2020) -
EPCT-09. CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES
por: Puccetti, Diane, et al.
Publicado: (2020)